⚡DOE Delays Effective Date for Energy Information Collection Rule
The Department of Energy (DOE) is publishing this document to respond to comments received on the direct final rule "Collection of Information Under the Energy Supply and Environmental Coordination Act of 1974," published on May 16, 2025. As a result, DOE delays the effective date of the direct final rule.
Learn More📈Nasdaq iShares Ethereum Trust Proposed Rule Change Notice
The Securities and Exchange Commission has published a notice regarding proposed amendments to the rules of the iShares Ethereum Trust, allowing in-kind creations and redemptions. This change aims to enhance market efficiency and ensure compliance with regulatory standards. The notice invites public comments and extends the Commission’s action period for further review.
Learn More💊FDA Notice on Patent Extension for KISUNLA Regulatory Review
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KISUNLA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.
Learn More⚡Delay of Effective Date for Electric Energy Transmission Permit Rule
Due to the receipt of significant adverse comments, the U.S. Department of Energy (DOE) is extending the effective date of the direct final rule "Application for Presidential Permit Authorizing the Construction, Connection, Operation and Maintenance of Facilities for Transmission of Electric Energy at International Boundaries," published on May 16, 2025.
Learn More📈NYSE National Connectivity Fee Schedule Amendments Overview
The Securities and Exchange Commission announces the proposed rule change for NYSE National, which modifies the Connectivity Fee Schedule, allowing connections to various third-party systems and data feeds. These changes aim to enhance user options and clarify associated fees, fostering a more adaptable trading environment.
Learn More📈NYSE Texas Proposes Rule Change for Connectivity Fee Schedule
The Securities and Exchange Commission has published a notice regarding NYSE Texas, Inc.'s proposed amendments to its Connectivity Fee Schedule. The changes aim to update third-party system access and data feed costs, providing additional options for users while maintaining fees for existing services. The amendments reflect evolving market demands and competitive considerations among users.
Learn More📊Proposed 2025 CAT Fees and Their Impact on Industry Members
The SEC has published a notice regarding the proposed rule change by Nasdaq GEMX to establish fees for Industry Members associated with the Consolidated Audit Trail (CAT). The fees aim to cover operational costs under the CAT NMS Plan for the latter half of 2025, impacting market participants significantly.
Learn More⚖️Postponement of MDI Investigation Determination by Commerce
The U.S. Department of Commerce has postponed the preliminary determination in its investigation of methylene diphenyl diisocyanate imports from China. This extension allows further evaluation of initial responses from respondents. The new deadline for the preliminary determination is set for September 10, 2025. Stakeholders must remain aware of potential implications for trade practices and regulatory compliance.
Learn More📄OMB Issues July 2025 Cumulative Report on Rescissions Proposals
Pursuant to the Congressional Budget and Impoundment Control Act of 1974, OMB is issuing a monthly cumulative report (for July 2025) from the Director detailing the status of rescission proposals that were previously transmitted to the Congress on June 3, 2025.
Learn More💊FDA Regulatory Review Period for HEMGENIX Patent Extension
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for HEMGENIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.
Learn More